title: Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma.
abstract: Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.
authors.affiliation: Department of Oral and Maxillofacial Surgery I, Okayama University Hospital of Dentistry, 2-5-1 Shikata-Cho, Okayama City, Okayama 700-8525, Japan. nakano@md.okayama-u.ac.jp
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakano
authors.forename: Chiharu Aoki
authors.initials: CA
authors.lastname: Sogawa
authors.forename: Norio
authors.initials: N
authors.lastname: Sogawa
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Mishima
authors.forename: Eiki
authors.initials: E
authors.lastname: Yamachika
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Mizukawa
authors.forename: Joji
authors.initials: J
authors.lastname: Fukunaga
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Kawamoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Sawaki
authors.forename: Toshio
authors.initials: T
authors.lastname: Sugahara
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Furuta
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D002945:Cisplatin / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008668:Metallothionein / Q000096:biosynthesis* / Q000235:genetics; D020033:Protein Isoforms / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014062:Tongue Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D020033:Protein Isoforms; D012333:RNA, Messenger; D008668:Metallothionein; D002945:Cisplatin